First human test of experimental cancer drug begins
NCT ID NCT07338838
Summary
This is the first human study of an experimental cancer drug called TQB3142. It aims to find the safest dose and understand how the drug moves through the body in 66 adults with advanced cancers that have stopped responding to standard treatments. The main goal is to check for side effects and determine the right dose for future testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital , College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.